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ABSTRACT
According to the National Center for Health Statistics, an estimated 22 million women have
undergone a hysterectomy procedure in the United States. The most common complication
during hysterectomies is accidental laceration of the urinary bladder during the surgery with
incidence between 0.2-8.3% with the current gold standard wound repair method being
sutures. Yet, sutures come with their own limitations in that they necessitate use of a
catheter and collection bag during healing due to preventing proper distention of the bladder
tissue at normal pressures. The long-term goal of our study is to eliminate the need for
suturing by creating a surgical adhesive that provides a combination of strength,
compliance, and biocompatibility for application to the bladder. However, current FDAapproved, commercially available tissue adhesives and sealants each have specific
limitations that make them unsuitable for bladder application. While addressing the
shortcomings of its predecessors, poloaxmines called Tetronic® (BASF Corporation) have
been used as the backbone of a novel tissue adhesive. Previous studies using Tetronic® have
exhibited higher strengths with increasing hydrogel content, but need further refinement to
meet the mechanical requirements for bladder wall tissue mechanics. Thus, it is
hypothesized that incorporation of a low molecular weight poloaximine, Tetronic® 304
(T304, MW: 1650 Da) would allow further increasing of hydrogel content and could yield
higher bonding and bulk strength for a tissue adhesive while not compromising gelation
time. Briefly, Tetronic® 304, and 1107 (MW: 15030 Da) were reacted with acryloyl
chloride to form terminal acrylate groups using previously established methods with the
final product characterized through NMR spectroscopy to determine the acrylation
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conversion percentage. The Tetronic® acrylate was crosslinked using dithiothreitol (DTT)
with the bulk strengths of various blends of the Tetronic®-based adhesive determined via
calculating maximum tensions from end-to-end tensile adhesion tests on collagen sheets. In
addition, punctured rat bladder specimens sealed with two blends of the hydrogel adhesive
were subjected to increasing intravesicular pressure until failure.

The maximum tension achieved from the tensile tests was for the 75/25 at 60wt% T304acrylate/T1107-acrylate group with a value of 0.65 N/cm ±0.06 N/cm (n=6). In addition, the
rat bladder puncture sealed with a 50/50 blend at 50wt % withstood pressure at an average
of 45.45±3.96 cm H2O. These results have demonstrated that using T304 has allowed for a
higher content of hydrogel to be incorporated into the Tetronic®-based adhesive, thus
increasing overall bulk strength. To further test the efficacy of this Tetronic®-based
adhesive, testing the hydrogel-based adhesive on the bladder both ex vivo and in vivo using
larger animal models will be necessary before moving onto clinical trials
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CHAPTER ONE
LITERATURE REVIEW

A. Clinical Motivation
According to the National Center for Health Statistics, 617,000 hysterectomies were
performed in 2004, and an estimated 22 million women have undergone this procedure in
the United States.1 Overall, an average of 622,000 hysterectomies have been performed in
the last decade nationally.2 The most common complication during hysterectomies is
accidental laceration of the urinary bladder during the surgery with incidence between 0.28.3%.1 Currently, the gold standard wound repair method for such injuries is suturing. Yet,
sutures come with their own limitations in that they necessitate use of a catheter and
collection bag during healing because they prevent proper distention of the bladder tissue
at normal pressures. Moreover, the uses of catheters can decrease overall patient quality of
life. Thus, an alternative approach for effective sealing of wounds is being investigated in
the present study.

B. Urinary Bladder Mechanics
When considering the suitability of a tissue adhesive for bladder application, it is essential
to understand the mechanical demands of the urinary bladder. Primary functions of the
urinary bladder are to contain large volumes of urine at low pressures3 and to void upon
smooth muscle contraction when bladder capacity is reached.4,5 The mechanical behavior
of the bladder wall tissue is reliant on the properties of smooth muscle cells and the
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extracellular matrix for their contractile function and tensile properties, respectively.5,6
Specifically, the microstructure, the interaction of the tissue components, and the resulting
overall response of the tissue changes from moment to moment.7 In one study, Nagatomi
et al. found that compared to normal rat bladders, 3-week spinal cord injury (SCI) rat
bladders exhibited a decrease in collagen content by 43%, and an increase in elastin
content by 260%, which explained the increased compliance of SCI rat bladders.8,9
Subsequent studies found that spinal cord injury (SCI) in rats prompted smooth muscle
hypertrophy (p<0.05) and changes in muscle orientation.6 While normal rat bladders
exhibited smooth muscle direction mostly in the longitudinal direction, 10 days after
spinal cord injury smooth muscles oriented in both the longitudinal and circumferential
direction.6 Toosi et al. expanded the scope of the experiment from 10 days to 10 weeks,
reporting changes in the biomechanical response of the urinary bladder wall tissue went
further than changes in overall bladder compliance. Particularly, changes in material class
from anisotropic (in normal rats) to isotropic (in 10-day SCI rats) to anisotropic (in 10week SCI rats), bladder composition (more collagen present in SCI rats), and architecture
(smooth muscle orientation from longitudinal to bimodal) were observed, indicating
constant remodeling of bladder wall tissue after the initial injury.10

Although mechanical testing of the bladder at the tissue level has provided valuable
information about its functional state8, the mechanical behavior of the whole bladder is
governed not only by the tissue properties, but also by bladder shape and size.11 Testing of
the whole bladder will further elucidate the physiological nature of its smooth muscle and
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ECM components under loading in vivo.5 Damaser and Lehman were the first to use
mathematical modeling and experimental data from dog bladders in vivo to predict the
effects of bladder shape on the pressure–volume relationship.3 They established
equilibrium equations for two types of spheroids: prolate and oblate to predict stress,
strain, and volume of the bladder tissue at various pressures. The oblate spheroid (Figure
1.1) made of urinary bladder material was shown to be more compliant than a prolate
spheroid or sphere. Defining bladder capacity as the volume of the bladder at the greatest
pressure (22 cm H2O in this study; normally between 20-60 cm H2O), oblate spheroids
had up to 70% more capacity than other models of the bladder.3 Greater bladder
compliance indicates a greater capacity to distend in response to pressure without
disruption. Since the use of sutures for wound repair restricts proper distension of the
whole bladder at normal physiological pressures, an alternative method of wound repair is
necessary.

Figure 1.1: Oblate Spheroid Model of Urinary Bladder
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C. Tissue Adhesives
Today’s most common methods for wound closure are sutures and surgical staples despite
a variety of limitations, including risk of infection, the requirement for anesthesia, and
difficulty in application and retention in soft tissues. These shortcomings in current
methods have led to the development of polymeric tissue adhesives that are capable of
being cured in situ.12 Tissue adhesives are defined as any substance that either acts as a
tissue connector or as a barrier for leakage.

In the past, tissue adhesives were only used in conjunction with sutures during wound
closure procedures.13 However, in order for surgical adhesives to serve as a viable
alternative to sutures and staples, they need to exhibit the ability to rapidly adhere as well
as maintain a close proximity to edges of wounds for an appropriate period of time.14 In
addition, an effective tissue adhesive should possess strong binding strength, ease of
application, biocompatibility with tissue, minimal reactivity with tissue, and practical cost
.15 Moreover, hemostatic potential, infection control capability, and internal sealant
bonding strength will add value to the tissue adhesives.16 An adhesive can furthermore
serve as a temporary scaffold while new tissue remodels the wound over the course of
time.12

D. Current Types of Tissue Adhesives
Although not specifically approved for urological applications, a variety of FDA-approved
adhesives and sealants are currently available on the market for surgical purposes. Major
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varieties of these include cyanoacrylates, BioGlue, fibrin glues, polyethylene-glycol
(PEG) based hydrogels.13 Additionally, collagen-based hydrogels are less commonly used,
but emerging as a viable option.13 These types of tissue adhesives have been thoroughly
analyzed as hemostatic agents and sealants in animal models as well as in clinical studies
of urinary fistula, cystotomy, and partial nephrectomy.17,18 Although there are benefits to
each of these tissue adhesive substances, there are noteworthy drawbacks such as
mismatch between the mechanical properties of the adhesives and native tissue,
complications related to residual toxicity, and difficulties with crosslinking.
a. Cyanoacrylate
Cyanoacrylate or “super glue” was first used as a tissue sealant in the 1940s, but its use
was limited due to the high levels of inflammation and histotoxicity it caused.17 The first
cyanoacrylate tissue adhesive was used for minor lacerations, but had limited physical
properties. Later, with further improvement, cyanoacrylate adhesives were used in
treatments for cornea perforation and wound leak keratotherapy19, as well as in facial
plastic and reconstructive surgery.15

In addition to reconstructive surgery, cyanoacrylates are generally used as an alternative to
suture closure. Cyanoacrylates are hard and brittle and may have insufficient flexibility for
the vibrant nature of in vivo conditions. Thus, these polymers are only used in external
applications such as skin closure and repair of corneal perforations.14 However, they do
possess numerous favorable characteristics including their ability to rapidly form flexible
bonds, act as an occlusive protective dressing, decrease inflammation, and ease of
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application. Many studies have noted that cyanoacrylate application only takes between
30-60% of the time as suture repair.15

Methyl-2-cyanoacrylate was the first cyanoacrylate compound to be used as a surgical
tissue adhesive.15 Over the years, histotoxicity levels of this adhesive have been shown to
be proportional to the length of their monomer side chain.15 More specifically, the toxic
effect of synthetic polymers is linked to types of breakdown products and the release
rate.19 Newer cyanoacrylate-based tissue adhesives, such as butyl-2-cyanoacrylate, have
longer side-chain derivatives, and thus, undergo a slower release and more efficient
clearing of the toxic byproducts from the local tissue.15 Moreover, the usage of inhibitors
of prostaglandin H synthetase, such as aspirin and indomethacin, has been shown to
decrease the cytotoxicity of cyanoacrylates up to eightfold in vitro.20

Today, the most widely used type of cyanoacrylate is octyl-2-cyanoacrylate, which was
approved by the FDA for use in topical wound closure in 1998.15 There are only two
cyanoacrylate brands currently authorized for use in the United States: Dermabond
(Ethicon, Inc.), a octyl-2-cyanoacrylate and Trufill n-BCA (Cordis Neurovascular, Inc.), a
combination of n-butyl cyanoacrylate and tantalum powder.13 Studies have shown that
tissue injury occurs because of cyanoacrylates’ poor compliance which motivated the use
of etheric oxygen to allow for the production of flexible monomers, enabled chain
rotation, and improved adhesive strength.14
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b. BioGlue
The next major group of tissue adhesives is based on the combination of purified bovine
serum albumin and glutaraldehyde glue, and is known as BioGlue (CryoLife Inc).13 It is a
proprietary FDA-approved (2000) compound generally used as a sealant aid to standard
methods of hemostasis in adults undergoing vascular surgery.17 At this time, BioGlue is the
only compound used in the United States for the restricted use of assisting in the repair of
aortic dissection by filling in the dissection; thereby closing the open cavity and providing
a stronger arterial wall.13 Strong bonds are created by the glutaraldehyde, which initiates
chemical reactions between the aldehyde groups of glutaraldehyde and the amine groups,
particularly lysine, of the albumin and tissue surfaces.21 More specifically, glutaraldehyde
links the amine groups from the bovine serum albumin to extracellular matrix proteins of
the target tissue, thus creating a covalent bond between the tissue and surgical adhesive.17

Although when compared with other similar currently available product, BioGlue has
greater bonding and sealing capabilities22, it does have limitations as well. For example,
researchers always consider possible tissue-related toxicity as a major drawback.17 In one
study, polymerized BioGlue with saline solution contained 100-200 µg/ml of
glutaraldehyde and was shown to be cytotoxic to both cell lines used. When BioGlue was
applied to a partial lung resection model, minimal edema and necrosis were present after 2
days and severe inflammation was apparent after 7 days.23 Other safety issues include local
tissue necrosis, pseudoaneurysm formation, and risks of eye, nose, throat, and skin
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irritation from the presence of glutaraldehyde.21 Moreover, LeMaire et al. reported that
BioGlue reinforcement in pigs impairs vascular growth and causes stricture when applied
circumferentially around an aorto-aortic anastomosis.22 Therefore, it was concluded that
since the use of polymerized BioGlue releases high amounts of toxic, residual
glutaraldehyde when not used on the aorta, it should not be used in pediatric patients until
further studies are conducted.22,23 It was also noted that even when BioGlue appears to
present many positive features as a product, the significant toxic potential of the glue
should be evaluated carefully.23 Finally, the inflammatory effects and long-term reaction to
BioGlue need to be better described and tested before the FDA will approve the further
expansion of its application.13

c. Fibrin Glue
The use of fibrin as an adhesive was first reported in 1940 by Young and Medawar, who
applied it as an adjunct to sutures of the peripheral nerves in an animal model during
microsurgery, and then subsequently by Seddon and Medawar in humans.24 Since 1998,
fibrin glue products, which are composed of thrombin and fibrinogen, have been approved
by the FDA for use in the reinforcement of colonic anastomoses, splenic trauma, and
cardiothoracic surgery.17 Fibrin sealants meet the requirements of an ideal tissue adhesive
to the greatest extent because both the adhesive and its resulting degradation products are
biocompatible and have properties that offer topical hemostasis, provide tissue
approximation, and possess sealant properties.13,17,25

8

Current brands of fibrin glues available in the United States are local blood bank products
as well as the commercial products, Hemaseel APR (Haemacure Corp.) and Tisseel VH
(Baxter Healthcare Corp.).13 Both products use human thrombin and aprotinin as an
antifibrinolytic agent.15 Like cyanoacrylates, fibrin glues are used to treat corneal injuries,
such as perforations and ulcers.26 When compared, 79% of eyes had successful healing of
corneal perforation treated with fibrin glue and 86% eyes treated with N-butyl-2cyanoacrylate, indicating that both tissue adhesives are effective in the closure of corneal
perforations up to 3 mm in diameter.26 While fibrin glue displayed faster healing and
generated less corneal vascularization than the cyanoacrylate, it required a much longer
time for adhesive plug formation.26

d. PEG Hydrogels
The final major category of current commercially available tissue sealants is polyethylene
glycol (PEG) hydrogels. Synthetic hydrogels, such as PEG-based polymers, can drastically
improve the support of soft tissue organs e.g. the heart or hard tissues e.g. bone.27 PEG
hydrogels as a whole are readily functionalized, nontoxic, non-immunogenic, and blood
compatible.28 Some commercially available PEG-based sealants are made up of PEG diols
modified with ester linkages that are degradable by water, and terminal acrylates for
photopolymerization.12 They are used for a vast array of clinical applications such as tissue
regeneration, drug delivery, coating, and postoperative adhesions prevention.28 In addition,
PEG hydrogels are used in research applications, such as model scaffolds for cell
migration.29
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CoSeal (Cohesion Technologies, Inc.) and AdvaSeal-S (Genzyme Corp.) are both PEGbased sealants approved by the FDA in 2000 for use as pulmonary sealants and as an
additive to blood hemostasis.17,21 CoSeal has demonstrated the ability to form adhesive
bonds with PTFE grafts and biological tissues in vitro while simultaneously exhibiting good
tissue compatibility and rapid gelation.30 Its efficacy has been demonstrated in that
hemostasis was achieved within 10 minutes in 86% of 148 patients in need of vascular
sealing.21 Another PEG-based sealant, Duraseal, is approved for dural sealing and forms a
hydrogel when its PEG ester component combines with trilisine amine with FD&C blue No.
1 dye, thus creating a water tight seal.21 Duraseal was shown to be 100% successful in
preventing cerebrospinal fluid leaks from dural closures.21 Reported tensile strengths have
demonstrated that both CoSeal and Duraseal are suitable as sealants for internal organs,
specifically arteries.30

Although PEG hydrogels are effective in sealing tissue, there are some associated
shortcomings as well. The primary safety concern of PEG-based sealants is swelling.
Because PEG hydrogels are water-based, they continue to absorb water and swell in vivo,
relative to initial volume dispersed.12,31 CoSeal swells up to 400% and is therefore never
used in place of sutures, staples or other mechanical closures. It is also not used in doses of
more than 16 milliliters since the safety of larger doses has not yet been verified.21
Comparatively, Duraseal only swells to 50%, but may be associated with other
complications such as inflammatory and allergic reactions if there is a known allergy to its
blue dye.21,32 Another limitation of PEG-based hydrogels lies in that they may contain a

10

water-soluble agent that requires a light source to polymerize and activate adhesion.13 This
photoactivation, a time-consuming process, makes these hydrogels difficult to work with for
surgeons in situations where immediate curing is required (i.e. massive hemorrhaging).
However, newer PEG hydrogels, such as CoSeal do not require this activation source.13

Recently, swellable PEG amine/dextran aldehyde composite materials have emerged as
controlled, biocompatible tissue adhesives.28 Together, the authors concluded that
PEG:dextran hydrogels can effectively adhere to tissue in a tunable manner, while not
compromising biocompatibility.28

E. Use of Tissue Adhesives in Urological Applications
Tissue adhesives have been tested in urological applications such as cystotomies and partial
nephrectomies with varying levels of success in both humans and animals.17
a. Cyanoacrylate
Studies related to urologic applications for cyanoacrylate-based adhesives have yielded
mixed results. For example, Grummet et al. concluded 2-octyl cyanoacrylate is not fit to be
used singularly for vesicourethral anastomoses during radical retropubic prostatectomy in
mongrel hounds.33 In contrast, Seifman and colleagues found that 2-octyl cyanoacrylate
was appropriate for closure of a large cystotomy in a rabbit model while demonstrating an
inflammatory response similar to traditional suture sealing.34 Although 2-octyl
cyanoacrylate (OCG) has been withheld from areas subject to repetitive movement (such as
the bladder), its performance in sealing large bladder wounds on pigs was proven to not be

11

affected by changing bladder volumes during normal filling.35 However, a disadvantage of
OCG was found in its low rate of biodegradability and potential to cause callus
formations.35

b.

BioGlue

BioGlue’s role in urological applications has not been assessed to date. However,
researchers hypothesize that it may prove to be beneficial in controlling bleeding in
procedures where chronic inflammation is present as well as in procedures where major
blood vessels need to be exposed, such as post-chemotherapy retroperitoneal
lymphadenectomies.17 Yet, there is the worry that application of BioGlue could cause
urinary obstruction.36

c. Fibrin Glue
Fibrin glue has been used as a sealant in a variety of urological applications such as
sutureless colposuspension in patients with stress incontinence and as an aide to hemostasis
in partial nephrectomy.25 It has also been used to close bladder fistulae and displayed
comparable results to microsurgery when treating vasovastotomies.24 The use of fibrin glue
for ureteral surgery has also been assessed in a number of animal models. For example,
Barrieras et al. performed a pyeloplasty in a porcine model using a suture-assisted fibrin
glue anastomosis. The immediate anastomotic leak point pressure was significantly lower
in the fibrin group (3.5 ±1.5 mm Hg) versus the control (17.3±5.4 mm Hg; P = 0.038).17
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Marcovich and associates compared 2-octyl cyanoacrylate (OCG), fibrin glue (FG), and
sutures for both open and laparoscopic repair of bladder wounds, using a pig model of
cystotomy. Their results showed that at 4 weeks, none of the six bladders of pigs treated
with OCG leaked at less than 200 mmHg pressure. In contrast, of the six pigs treated with
FG, three died from a huge urine leak, one leaked, and two did not leak at less than 200
mm Hg at 4 weeks. From these findings, it was concluded that OCG is the only viable
alternative to sutures for sealing of large bladder wounds and fibrin glues may be effective
in bladder injury closure when tissue approximation is small and intraluminal pressures are
low.35 However, it was also noted that reduction in adhesive capacity upon contact with
urine due to fibrinolytic activity of urokinase would remain one of the concerns associated
with the use of fibrin glue in urological applications.25

d. PEG Hydrogels
PEG hydrogels have been tested in porcine laparoscopic partial nephrectomy (LPN) models
and provided hemostasis at physiological pressures up to 100 mmHg.37 In addition, Park and
colleagues found that PEG hydrogels provided hemostasis for LPN in a porcine model and
detected no cell-mediated immune responses to the sealant after 2 weeks, with the hydrogel
being completely absorbed by the animal within 6 weeks.38 However, compared to fibrin
glue, the PEG hydrogel-based CoSeal did not adhere as well to the nephrectomy bed during
LPN, signifying that further refinements need to be made before synthetic hydrogel sealants
are suitable for urological applications.36
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F. Use of Tetronic® as a Tissue Adhesive
In order to address the issues associated with currently available tissue adhesives and
sealants, Cho et al. began exploring thermosensitive polymers called poloxamines or
Tetronic® (BASF Corp.) as the backbone material of a soft tissue adhesive.12 Poloaxmines
are a family of 4-arm polypropylene oxide (PPO) - polyethylene oxide (PEO) block
copolymers with a hydrophobic PPO core surrounded by a hydrophilic PEO shell and can be
used to prevent swelling of hydrogel-based tissue adhesives.12,38 Previously, Tetronic® was
studied as a network material to encapsulate human foreskin fibroblasts by way of “tandem
gelation”, a two-stage process combining reverse, thermally-induced gelation and covalent
crosslinking of termini functionalized with reactive groups.40,41 A study by Cho et al. tested
a hypothesis that the combination of noncovalent and covalent gelation of Tetronic®
hydrogels would provide an improvement for mechanical properties of tissue
sealant/adhesive applications compared to PEG-based hydrogels that were created only by
covalent crosslinking.12 Specifically, Tetronic® 1107 (T1107; MW 15,030 Da) and
Tetronic® 904 (T904; MW 6700 Da) were acrylated via dichloromethane and acryloyl
chloride and polymerized by Michael-type addition.12 Both hydrogels, T1107-acrylate and
T904-acrylate, were then characterized for mechanical and tissue bonding properties,
gelation point, swelling behavior, viscosity, and cytotoxicity.12 The results of this study
provided evidence that all blends (100% T1107-acrylate, 75/25 T1107-acrylate/T904acrylate and 50/50) containing T1107-acrylate chemically crosslinked below physiological
temperatures (37°C), while 100% T904-acrylate and the control 4-arm acrylated PEG did
not gel within the temperature range of 4-40°C. Gelation time increased with decreasing
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T1107-acrylate content (23.5±2.12 s for 100% T1107; 153.33±5.77 s for 100% T904). The
stiffness and strength of Tetronic® hydrogels were greater than the PEG control and
increased with increasing temperature and T904-acrylate content to a maximum value of
400 kPa at 37°C. Tissue bonding strength also increased with increasing T904 content
(maximum of 25 kPa), which was comparable to commercial fibrin glue and far exceeded
the control PEG hydrogel.12 Together, it was concluded that all mechanical properties of the
hydrogels were temperature dependent and that using tandem gelation contributed positively
to material properties.

More recently, Barrett et al. reported that Tetronic® backbones terminated with catechols
including gluataric anhydride, pyridine, dopamine and TEA, served to increase both
adhesive and cohesive strengths of the hydrogel tissue adhesive.41 Briefly, the results of lap
shear testing revealed that strength values for modified Tetronic® 1107-acrylate gels with
varying levels (150-250 ml/mg) of these catechols ranged from 31.9-48.7 kPa, which was
marginally stronger than a DOPA-modified PEG (30.4 ± 3.39 kPa) from a previous study.42
However, the adhesive strength was much higher than that of the catechol-modified 4-arm
PEO control (12.7 kPa).41 Although the highest lap shear adhesive strength from this study
is well above the mean value reported by Cho et al. (25 kPa) , when comparing results
parameters such as testing methods, crosslinking mechanisms, and equipment must be taken
into account.12,41 For example, Cho et.al and Barrett et al. both used lap shear testing on
animal specimens. However, Cho’s samples were subject to overnight curing at 37°C in a
humidified atmosphere and soaked in PBS before testing.12 In contrast, Barrett’s samples
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were initially cured for one hour at 37°C while glued to aluminum fixtures and covered by
PBS-soaked gauze.41Additionally, a 100 gram weight was placed on the aluminum fixture
assembly after which the samples were submerged in PBS for one hour before testing.41
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CHAPTER TWO
PROJECT RATIONALE
The long-term goal of our study is to eliminate the need for suturing by creating a surgical
adhesive that provides a combination of strength, compliance, and biocompatibility for
application to the bladder. However, current FDA-approved, commercially available tissue
adhesives and sealants each have specific limitations that make them unsuitable for bladder
application. While addressing the shortcomings of its predecessors, the more recent attempt
to use poloaxmines as the backbone of a novel tissue adhesive needs further refinement to
meet the mechanical requirements for bladder wall tissue mechanics. Given that the lower
molecular weight T904-acrylate exhibited higher strengths with increasing hydrogel
content, it is hypothesized incorporation of an even lower molecular weight poloaximine
would allow further increasing of hydrogel content and could yield higher bonding and
bulk strength for a tissue adhesive. This Master’s thesis focused on increasing the overall
bulk strength of the Tetronic® adhesive by using a low molecular weight Tetronic® 304
(T304, MW: 1650 Da), while not compromising the strength and gelation time. This study
is divided into three project aims:
1) To develop a synthesis route for T304-acrylate with high conversion efficiency
and product yield.
2) To determine blend ratios and weight percentage of T304-acrylate and T1107acrylate with the highest mechanical strength.
3) To demonstrate the efficacy of the Tetronic® tissue adhesive in an ex vivo bladder
test.
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CHAPTER THREE
MATERIALS AND METHODS
A. Materials
Tetronic® T1107 (MW 15030 Da) and T304 (MW 1650 Da) were acquired from the BASF
corporation (USA) as free samples. Acryloyl chloride, celite fine 500 and 4-methoxyphenol
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Toluene (HPLC grade),
anhydrous ether (BHT stabilized), hexanes (HPLC grade), and anhydrous sodium sulfate
were purchased from Fisher Scientific (NJ, USA). Dichloromethane (HPLC grade),
triethylamine (TEA), dithiothreitol (DTT), sodium bicarbonate, calcium hydride and CDCl3
were purchased from Acros Organics (NJ, USA), a branch of Fisher. Dichloromethane was
dried with calcium hydride and stored over molecular sieves (Grade 514, Type 4A, 8-12
mesh, Acros Organics).
Table 3.1: Characteristics of specific Tetronics

Tetronic
Type

Molecular
Weight (Da)

Mean
Number of
EO Units per
PEO Block

T304

1650

3.7

4.3

T1107

15030

60

20

18

Mean
Number of
PO Units per
PPO Block

Physical
State at 25°C
(RT)
Liquid
Powder

Figure 3.1: General Structure of Tetronic® Acrylate.
Blue boxes indicate terminal acrylate groups

B. Acrylation of Tetronic®
a. Preparation of T1107-acrylate
Acrylated T1107 was prepared by reaction of the raw Tetronic® terminal hydroxyl
groups with acryloyl chloride. All glassware was cleaned with sodium hydroxide
solution, rinsed with DI water followed by one acetone rinse, and completely dried in a
60°C oven overnight. T1107 (30 g) was dehydrated by azeotropic distillation with
toluene over two hours in an oil bath at 130°C, which was then allowed time to reflux
and then subsequently removed by rotary evaporation (Buchi Rotavapor®, Switzerland)
at 90°C. After cooling to room temperature, dehydrated T1107 was dissolved in 120 ml
of dry dichloromethane and TEA (4 mmol, 1.115 ml) was added. On an ice bath, acryloyl
chloride (8 mmol, 1.30 ml) in 60 ml of dry dichloromethane was then added dropwise
over two hours and the reaction was allowed to continue at room temperature for 24
hours. The reactant was filtered through celite fine 500 to remove TEA-HCl salt, and then
paper-filtered to remove the celite. The solvent was removed by rotary evaporation at
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room temperature. The residue was precipitated in 500ml of cold ethyl ether (-20°C),
recovered by filtration, and dried under vacuum for a few hours. The product was
redissolved in dry dichloromethane (300ml), washed repeatedly with 30ml of 10% w/v
sodium bicarbonate solution until the pH was neutral, and then washed with deionized
water (30 ml each) until the pH of the water faction was neutral. Next, the product was
dehydrated with anhydrous sodium sulfate until the solution became clear. After paper
filtration, the remaining solution (dichloromethane+ product) was decanted and removed
by rotary evaporation at 25°C. The residue was precipitated and washed 3 times with cold
ethyl ether (-20°C). The final product was recovered by filtration and dried in a vacuum
desiccator overnight. The final structure and acrylation efficiency (%) were determined
by 1H-NMR (Bruker Avance-300MHz) using a CDCl3 (chloroform) solvent.43

b. Preparation of T304-acrylate
T304-acrylate was synthesized in a similar manner to T1107-acrylate with minor changes
to account for reduced thermal stability and different solubility properties. Prior to
experimentation, unmodified T304 was dissolved in dichloromethane, subjected to rotary
evaporation and precipitated in hexane to test product recoverability. Following the initial
reaction setup, the residue was precipitated in a total volume of 500ml of the cold
hexane/ethyl ether (50/50 volume ratio), and stored at -20°C to allow the precipitated
product to settle overnight. After approximately 24 hours, the hexane/ethyl ether
supernatant solution was quickly and gently decanted and the product was redissolved in
300 ml dichloromethane. Subsequently, the solution was washed repeatedly with 30 ml of
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10% w/v sodium bicarbonate solution until the pH was neutral. This was followed by
deionized water washes with 30 ml each until the pH of the water fraction was neutral, and
the remaining product was dried with anhydrous sodium sulfate (approximately 4-6 times
or until the solution became clear). Relatively small amounts of sodium sulfate was used
in order to preserve as much of the product as possible. The product dissolved in
dichloromethane was again subjected to rotary evaporation at 30°C and concentrated in
the presence of 2 chips of 4-methoxyphenol. The residue was precipitated in a total
volume of 500ml of hexane/ethyl ether and washed 3 more times with cold ethyl ether.
The final product was recovered by decanting of the ethyl ether and dried under vacuum
within a desiccator at 4°C for 6 to 8 hours. 1H-NMR was performed to analyze the final
structure and acrylation efficiency (%) using 25 mg of product in 1 ml chloroform solvent
(Cho and Cribb).

C. Mechanical Testing of Tetronic® Adhesive
Prior to mechanical testing, the appropriate weight of Tetronic® acrylates (Table 3.2) was
first mixed with 1ml of PBS (50mM) on a rocker in a cold room, protected from light for
1-2 days.
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Table 3.2: T304-acrylate/T1107-acrylate blend ratios with corresponding DTT amounts

a. Testing with a Model Tissue
Collagen casing was sectioned into ½ inch-wide strips using a previously created printed
template and placed in a fixture that maintained end-to-end contact between two pieces
(Figure 3.2). The strips were then hydrated in PBS within a 37°C water bath for one hour.

Figure 3.2 End-to-End Configuration
For testing of each specimen, 50 microliters of T304-acrylate/T1107-acrylate blend was
mixed with appropriate volumes of dithiothreitol (DTT) solution (10%) according to Table
3.2 and vortexed until the solution crosslinked reached a certain viscosity, where it formed
a gel-like substance, but was still in a liquid enough state for extraction by a 1 cc syringe.
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The solution was judged to be in this “gel-like” state” when it did not flow within the
mixing tube when subjected to tube inversion. Reproducibility was created through
application of set vortex speeds correlating to gelation times among samples from the same
Tetronic® blend. 50 µl of the mixture was then applied to the joint between the two pieces
of collagen casing and allowed to cure under hydrated conditions in the 37°C water bath for
30-45 min. Immediately before testing, specimen thickness was measured using a digital
caliper. Using an MTS Synergie 100 (Figure 3.3) with a 10 N load cell, specimens were
subjected to uniaxial tensile load at a rate of 5 mm/min until bonded joints broke. To avoid
slippage, the ends of the specimen were wrapped with sandpaper (P400 grade) within the
grips of the testing system. The data were reported as maximum tension to failure (N/cm).

Figure 3.3: Tensile Testing Configuration
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D. Viscoelastic Characterization of T304 and T1107
a. Gelation Analysis
To characterize the viscoelastic behavior of the Tetronic® hydrogels, unmodified
(reverse thermal gelation) and acrylated (tandem crosslinking via reverse thermal gelation
and Michael-type addition)12, T304 and T1107were dissolved in PBS at three different
ratios of 100/0, 0/100, and 50/50 (at 30wt % and 50wt % concentration).
1. Reverse Thermal Gelation
Rheological analysis on unmodified Tetronic® macromers was performed using the
AR2000 rheometer (TA Instruments, Newcastle, DE) with a parallel plate configuration
(40 mm diameter). 60 µL of the test specimens were placed on the bottom plate (precooled to 4°C via ice bath), and then the top plate was lowered to create a 0.15 mm gap
between the two plates. A temperature sweep from 4-40°C at 2°C/min was conducted at a
constant frequency of 0.1 Hz. The temperature at which the storage (G’) and loss (G’’)
moduli met was determined as the gelation point.12
2. Tandem Crosslinking
Parallel plate geometry was used again to analyze the crosslinking characteristics of
acrylated Tetronic® macromers. The macromers were dissolved in PBS and then
covalently crosslinked with DTT, a donor of the thiol group. The T304-acrylate/T1107acrylate solutions (60 µl of 100/0, 50/50 at 30 and 50wt %, 0/100 only at 30wt %) and
DTT (10µl stored at 4°C until testing) were mixed and vortexed at room temperature. The
mixture was placed on the bottom plate (pre-warmed to 37°C) of the AR2000 rheometer,
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and the top plate was lowered to create a 0.15 mm gap between the two plates.
Oscillatory shear strain of 1% was applied immediately at a constant frequency of 0.1 Hz.
Storage and loss moduli were recorded as a function of time and gelation time was
determined as the instance at which the lines for G’ and G” crossed over.12

E. Ex Vivo Adhesive Testing on Rat Bladder
Rat bladders were obtained from Pel-Freez Biologicals Inc. (Rogers, AR) and stored in
30% sucrose solution at 4°C until testing. Prior to testing, a small, approximately 2 mm
puncture was made on the dome of the bladder using an 18 gage needle. Using a 1 cc
syringe, the Tetronic®/DTT mix (500 µl to 50 µl ratio) was applied to the hole and
allowed to cure for 1 hour within a saline solution-containing petri dish in the 37°C water
bath. After curing, the rat bladder was mounted via sutures and superglue on a shaved 18
gage needle within a plastic container which was filled with saline solution until the
bladder was submersed. The specimen was subjected to increasing intravesicular pressure
using a Harvard Apparatus 11 Plus Pump (Harvard Apparatus; Hollison, MA) and a 60
ml syringe at a flow rate of 0.1 ml/min until failure, which was evidenced by saline
solution colored with calcein blue dye, indicating leakage.

F. Statistical Analysis
Quantitative data for maximum tension and maximum intravesicular pressure withstood
by the Tetronic®-based adhesive were statistically analyzed using the commercial
statistics software, SigmaStat 3.5. Following a one-way analysis of variance (ANOVA)
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test, when statistical significance was observed, post-hoc comparisons were made using
the Tukey method. Data sets with p values of less than 0.05 were considered to be
statistically significant.
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CHAPTER FOUR
RESULTS
A. 1H-NMR (CDCl3) Characterization of Tetronic® Acrylate
T1107-acrylate (unmodified: Figure 4.1, acrylated: Figure 4.2) and T304-acrylate
(unmodified: Figure 4.3, acrylated: Figure 4.4) were characterized via NMR
spectroscopy, with peaks present at locations including δ= 1.2 (PPO CH3), 3.65 (PEO
CH2), 4.32 (-CCH2OC (=O)), and 5.8-6.4 (2H, acrylic –CH2) ppm. The acrylation
efficiency conversion percentage, calculated based on the ratio of the integrals of the
PEG backbone (δ = 3.4~3.7) and the acrylate peaks, (δ = 5.8–6.4)12 were 93-95% for
T1107-acrylate and 62-74% for T304-acrylate over two synthesis reactions for each
Tetronic® type (Table 4.1).
Table 4.1: Result summary of acrylation for Tetronics (mean± SD; n=2 reactions)

T304

Average
Acrylation
Conversion
Acquired via
NMR Spectra
68±8.5%

Average Overall
Product Yield
(%)
53±7.1%

T1107

94±1.4%

73±8.9%

Tetronic Type
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PEO/PPO Backbone

Figure 4.1: 1H-NMR spectrum for unmodified T1107 (T1107: n = 60, m = 19)
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PEO/PPO Backbone

Methyl Group

Acrylate Groups

Figure 4.2: Tetronic® structure (T1107: n =60, m =19) and 1H NMR
spectrum of T1107-acrylate
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PEO/PPO Backbone

Figure 4.3: 1H-NMR spectrum for unmodified T304 (T304: n =3.7, m =4.3)
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PEO/PPO Backbone

Methyl Group

Acrylate
Groups

Figure 4.4: 1H NMR spectrum of T304-acrylate (T304: n =3.7, m =4.3)
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B. Mechanical Testing of Tetronic® Adhesive
The end-to-end tensile testing of collagen sheets bonded with Tetronic® adhesives
revealed that at 40wt % (w/v), T304-acrylate/T1107-acrylate at 75/25 and 50/50 ratio
blends exhibited a similar adhesion strength to T304-acrylate alone (p > 0.05) with an
average maximum tension of 0.41 ± 0.06 (mean ± SEM, n=6) and 0.43 ± 0.03 N/cm
(n=6), respectively, compared to 0.32 ± 0.07 N/cm (n=3) (Figure 4.5). In comparison,
at 50wt %, the adhesive strengths were also similar (p > 0.05) for all three blends tested
(T304-acrylate alone: 0.59 ±0.07 N/cm for n=3, 50/50: 0.56 ± 0.05 N/cm for n=6, and
75/25: 0.52 ± 0.08 N/cm for n=3), which were greater (but not significantly) than that
of the 40wt % formulations. The highest strength value achieved was for the 75/25
T304-acrylate/T1107-acrylate group at 60wt % with a value of 0.65 N/cm ±0.06 N/cm
(n=6), which was similar to the 50wt % blend groups, but exhibited significantly
stronger (p < 0.05) adhesive strength than the other 50/50 blend ratio groups at both 40
and 50wt %. There was also significant statistical difference among the 75/25 blend
ratios for 40, 50, and 60wt %.
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Figure 4.5: End-to-End Testing Mechanism for T304-acrylate/T1107-acrylate
ratios at 40wt %, 50wt %, and 60wt% (ratio/wt%), (n=6 for 75/25/40 50/50/40,
50/50/50 and 75/25/60; n=3 for all other groups). Letters indicate significant
difference between groups.
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C. Viscoelastic Characterization of Tetronic®
a. Gelation Analysis
1. Reverse Thermal Gelation
A temperature sweep from 4-40°C at 2°C/min was performed for the 100% T304 (at 30
and 50wt %), 100% T1107 (at 30wt %) and a 50/50 blend (at 30 and 50wt %). Sol-gel
transition temperatures (at which the storage (G’) and loss (G”) moduli met) were
20.05±0.28°C for 100% T1107 and 36.2±1.64°C for the 50/50 blend at 30wt %. In
contrast, gelation temperatures at 50wt % for the 50/50 blend were 36±1.03°C (Figure
4.6) and 34.7±0.45°C (Figure 4.7) for the 100% T304 (Table 4.2). Data were not
acquired for 100% T1107 at 50wt % and 100% T304 at 30wt %. as it either gelled too
fast to test or did not gel within the temperature range tested.
Table 4.2: Sol-gelation temperature of three Tetronic® blends %
for a temperature sweep of 4-40°C (n=2)
T304/T1107
composition (total
100%)

Reverse Thermal
Gelation: Gelation
Point (°C) @
30wt%

Reverse Thermal
Gelation: Gelation
Point (°C) @
50wt%

100/0

N/A

36.0±1.03

50/50

36.2±1.64

34.7±0.45

0/100

20.1±0.28

N/A
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Figure 4.6: Temperature sweep of 50/50 blend
of T304-acrylate/T1107-acrylate at 50wt %
at 50wt %
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Figure 4.7: Temperature sweep of 100% T304-acrylate at 50wt %.
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2. Tandem Crosslinking
The gelation times were measured for three blends of T304-acrylate/T1107-acrylate
at 50wt % when covalently crosslinked with DTT at 30 and 50wt%. The 100%
T1107-acrylate’s gelation time was 26.6±2.28 seconds for 30wt %, but did not yield
viable results at 50wt % due to rapid gelation. Gelation times 7 minutes and 19
minutes on average (Table 4.3) for the 50/50 blend and 100% T304-acrylate at 30wt
% (n=2), (Figure 4.8) respectively. In comparison, the average was 5 minutes and 11
minutes for the same blend ratios at 50wt %.
Table 4.3: Gelation times of three Tetronic® blends when crosslinked with DTT
(n=2)
T304-acrylate/T1107 acrylate composition
(total 100%)

Tandem Crosslinking:
Gelation Time (s) @
30wt%

Tandem Crosslinking:
Gelation Time (s) @
50wt%

100/0

1143.8±12.14

629.3±6.02

50/50

474.1±17.31

304.5±8.49

0/100

26.6±2.28

N/A
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Figure 4.8: Chart of 100% T304-acrylate subjected
to oscillatory shear until gelation at 30wt %
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D. Ex Vivo Adhesive Testing on Rat Bladder
Rat bladders with approximately 2 mm punctures sealed with 100% T1107-acrylate at
30wt % withstood an average of 29.91±3.21 cm H2O before failure (n=3). In contrast,
T304-acrylate/T1107-acrylate (50/50) at 50wt % withstood significantly (p<0.05)
higher pressure at an average of 45.45±3.96 cm H2O (mean ± SEM, n=5) (Figure 4.9)
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Figure 4.9: Effect of intravesicular pressure-loading rat bladder punctures
sealed with two different Tetronic® adhesives (n=3 or 5)
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CHAPTER FIVE
DISCUSSION
A. Characterization of Tetronic® Acrylate
The goal of the present study was to investigate the effect of blending a low MW T304 on
overall bulk strength of a Tetronic® 1107-based tissue adhesive, which was previously
investigated 12,39,40,41 For T1107, the 94 ±1.41 % average percentage conversion of the
terminal hydroxyls to acrylates obtained in the present study was on par with that reported
previously by Cho et (97% average)12, indicating that a similar level of chemical
crosslinking and bulk strength of this component could be expected. In contrast, average
acrylate conversion percentage for T304 was 68% ± 7.49 with a relatively low product
yield compared to T1107-acrylate (53% vs. 73%), which may be attributed to the
differences in physical state (solid for T1107 and liquid for T304 at RT). We speculated in
early stages of the study that large amounts of T304 were lost during the sodium sulfate
drying and ethyl ether/hexane wash steps of the acrylation process based on differences in
the amount of product observed before and after these specific steps. Therefore to improve
both acrylation efficiency and product yield for T304, we modified the synthesis protocol
to include longer reflux durations for the distilled product, efficient rotary evaporation by
allowing more time to elapse in order to fully evaporate either toluene or DCM, and more
sodium sulfate drying steps at smaller volumes. Using this modified protocol, T304acrylate product yield almost tripled from 17% to an average of 53%. Additionally,
acrylation percentage increased from 39% to an average of 68%. Further modification of
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the synthesis process such as even slower addition of acrloyl chloride to the product may
lead to an even higher acrylation percentage for the T304-acrylate.

B. Mechanical Testing of Tetronic® Adhesive
The results of the present study demonstrate that T304-/T1107-acrylate blends (Figure
4.5) were mechanically stronger compared to the T904-/T1107-acrylate blends previously
tested (unpublished data, Appendix C, Figure C.1). More specifically, the average
maximum adhesive strengths at a 75/25 and 50/50 ratio of T304-/T1107-acrylate values,
0.41 ± 0.06 N/cm and 0.43±0.03 N/cm (Figure 4.5), were much greater than the same
ratios for T904-/T1107-acrylate (40wt %), 0.15±0.02 N/cm (n=9) and 0.07±0.01 N/cm
(n=9) (Figure C.1), respectively. A similar trend was also observed at 50wt %.
Differences in strength between the T304 and T904 are attributed to the much lower MW
of the T304 (1650 Da vs 6700 Da), which enables more Tetronic® content to be
incorporated into the hydrogel adhesive. Among the blends tested to date, the 75/25 ratio
of T304-/T1107-acrylate at 60wt % exhibited the highest bulk strength, corroborating with
our original hypothesis that the higher content of hydrogel by incorporation of the low
MW T304-acrylate would increase the strength of the tissue adhesive. Statistical analysis
verified this by showing significant differences (p<0.05) among various weight
percentages of the same blend ratio (i.e. 75/25 at 40, 50, and 60wt % and 50/50 at 40 and
50wt %), but not among specific blend ratios within one weight percentage category.
However, it must be noted that T1107-acrylate did contribute to the bulk strength of the
adhesive as evidenced by increases from the 75/25 to 50/50 ratios by manipulating the
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amount of T1107-acrylate content for both 40wt % (0.41 ± 0.06 N/cm to 0.45 ± 0.05
N/cm) and 50wt % (0.52 ± 0.08 N/cm to 0.56 ± 0.05 N/cm. Yet, a “ceiling” has been
established for how much T1107 content can be included in the surgical adhesive (30wt
%) before rapid thermal gelation occurs. Catalyzed by the large molecular weight of
15,030 Da and PEO/PPO ratio of the gel, T1107 has a high capacity for reverse thermal
gelation in both its unmodified and modified forms.12 This theory is also illustrated in the
fact that mechanical testing results were unattainable for high weight concentrations of the
T1107 (i.e. 25/75 T304-/T1107-acrylate at 40wt % and up) due to gelling of the Tetronic®
hydrogel before it could be applied to the collagen casing surface.

To estimate a target strength for the Tetronic®-based adhesive, the Law of LaPlace was
applied at physiological conditions of 40 cm H2O voiding pressure, 600 ml capacity, and
12 cm distended bladder diameter. Calculated as a function of bladder thickness, diameter
and intravesicular pressure, it was determined that the surgical tissue adhesive must
withstand tensions approximately between 3.2-4.8 N/cm. While these values were not
reached in the present study, failure during mechanical testing was observed as “cohesive
failure” as the material broke at the interface between the two collagen strips, but was still
present on the surfaces of the debonded pieces. This type of failure indicates that the
adhesive strength of the Tetronic® hydrogel is stronger than cohesive strength. It is
predicted based on results generated by mechanical testing of the adhesive that higher
weight percentages of T304-acrylate (in the range of 70-80wt %) in the hydrogel-based
tissue adhesive will aid in yielding even higher bulk strengths. Additionally, it is projected
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that bond strength can also be improved through copolymerization of the Tetronic®
hydrogels with PEG/dextran hydrogels or acrylate/aldehyde difunctional poloaxmers, in
addition to functionalizing the Tetronic® hydrogel with catechols.12,27,28,41,45,46

C. Viscoelastic Characterization of Tetronic®
Concentrated aqueous solutions of Tetronic® have been shown to undergo physical
gelation at temperatures in the 20-35°C range due to the hydrophobic transition associated
with their PPO segments.41 At 30wt %, the 100% T1107 gelled at 20.05±0.28°C (Table
4.2). In contrast, the 100% T304 at 30wt % did not gel under the temperature range tested
in (4-40 C) as Cho et al. observed for the 100% T904 in a previous study, suggesting that
both T304 and T904 lack reverse thermal gelation at relatively low concentrated
solutions.12 Both the 100% T304 and 50/50 blend at 50wt %, however, transitioned from a
liquid to solid state at physiological temperatures of 36±1.03°C and 34.7±0.45°C (Table
4.2), respectively.12 Moreover, T304/T1107 at 30wt % and a 50/50 blend ratio gelled at a
higher temperature, 36.2±1.64°C, than the same blend ratio for T904/T1107 which gelled
at 23.67±1.22°C. This demonstrates that adhesives containing T304 can gel upon contact
with tissue at physiological temperatures (37°C).12 Yet, it is projected that since the 100%
T304 at 30wt % failed to gel at physiological temperatures, either a higher molecular
weight Tetronic should be used in conjunction with the T304 or a higher weight
percentage of T304 alone should be used to create the Tetronic®-based tissue adhesive.
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The increase in gelation time with increasing T304-acrylate content observed in the
present study (Table 4.3) is associated with the diminishing contribution of the T1107acrylate component to reverse thermal gelation.12 This is evidenced in the drastic
difference in gelation times between the 50/50 blend (304.5±8.49 sec) and the 100%
T304-acrylate (629.3±6.02 sec), demonstrating the impact T1107 has on gelation time.
When comparing the gelation times for 100% T304-acrylate and the 100% T304-acrylate
in Cho et al.’s study12, the 7.5-fold difference 153.33±5.77 sec versus 1144±12.1 sec, was
thought to be attributed to the difference in acrylation efficiency (87% vs. 68 %), and in
molecular weights. This was because neither product contained T1107, and the gelation is
due mainly to the covalent crosslinking, mediated by the presence of DTT. Moreover, the
present study demonstrated that the gelation time of the 50/50 blend at 50wt % was lower
than that the same blend at 30wt %. These results illustrate the impact of hydrogel content
and an increased number of crosslinking sites on the ability to adjust gelation time.
Finally, since the Michael-type addition is a pH-dependent reaction, the gelation times and
reaction rates for covalent crosslinking can be further tuned for desired applications by
adjusting the pH of the solution reactants.12

D. Ex Vivo Adhesive Testing on Rat Bladder
Because the adhesive developed in the present study was originally meant for repair of
bladder injuries, ex vivo testing was conducted using a custom device44 on rat bladders
submersed in saline solution with the purpose of approaching more physiological
conditions than tensile testing with tissue segments. The 50/50 blend of T304-
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acrylate/T1107-acrylate at 50wt % withstood pressures at an average of 45.45±3.96 cm
H2O, higher pressures than the control group, the 100% T1107-acrylate at 30wt %
(29.91±3.21 cm H2O). These results showed that this blend of Tetronic® adhesive was
effective at sealing a rat bladder puncture at physiological pressures. However, further
tests need to be conducted following repeated cycling of the bladder in order to measure
long-term durability of the adhesive. It also must be noted that in the present study, only
two blend ratios of T304-acrylate/T1107-acrylate were tested in these conditions.
Therefore, it is predicted that blends with higher levels of Tetronic® contents (75/25 at
60wt %), will withstand higher levels of intravesicular pressure.

46

CHAPTER SIX
CONCLUSION
The results from the present study demonstrated the impact of a low molecular weight
Tetronic®, T304, on the bulk strength of a hydrogel-based bladder adhesive. Specifically,
using T304 instead of T904 has allowed for a higher content of hydrogel to be
incorporated into the Tetronic®-based adhesive, thus increasing the weight percentage to
increase overall bulk strength. Additionally, the contribution of T1107 to the bulk
strength and gelation time of the Tetronic®-based adhesive has been demonstrated.
Therefore, further fine tuning of T304-acrylate/T1107-acrylate blends ratios as well as
improving the acrylation efficiency of the T304 should allow for achieving the balance
between high overall bulk strength and clinically relevant gelation times.

47

CHAPTER SEVEN
LIMITATIONS AND FUTURE WORK
A.

Limitations and Potential Solutions
a. Characterization of Tetronic® Acrylate



Acrylation efficiency of the T304 (68%) was lower in comparison to T1107 (94%)
possibly due to rapid addition of acrloyl chloride. This conversion percentage may be
improved by adding the acrloyl chloride much more slowly which will provide more
time for the reaction and more efficient filtration of the TEA-HCl salt to remove
excess chlorides.



Product yield of T304 was also low in comparison to T1107 mainly due to the
product loss during the sodium sulfate drying steps. This could be improved by more
sodium sulfate drying steps at smaller volumes.



In the present study, PBS was used to dissolve Tetronic® without further adjustment
of pH. Since crosslinking rate of Tetronic®-acrylate is highly sensitive to pH
variability, in future studies, pH levels of the T304 should be monitored(and adjusted
accordingly) at regular intervals and maintained in the desired range (ideally 7.2-7.4)
before it is used as a tissue adhesive.

b. Mechanical Testing of Tetronic® Adhesive


Since the main goal of the present study was to improve the bulk strength of the
Tetronic®-based adhesive, mechanical testing was performed in the end-to-end
configuration. By completing shear adherence tests of T304-acrylate/T1107-acrylate
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with the same blend ratios as T904-acrylate/T1107-acrylate previously tested, a direct
comparison could be made as to how incorporation of T304 in the hydrogel-based
adhesive improves the bond strength.
 Tetronic® adhesives on collagen casings were cured under a hydrated condition for
one hour prior to mechanical testing for all blend ratios and weight percentages to
maintain consistency between the previous and present studies. Since the
viscoelastic characterization demonstrated that gelation of T304/T1107 (50/50)
occurs in 5 minutes, future mechanical testing may be performed with shorter curing
times in order to be more clinically relevant.

c. Viscoelastic Characterization of Tetronic®
 Temperature sweep tests were only performed on unmodified Tetronic® solutions to
characterize the reverse thermal gelation behavior of the polymers. Conducting these
tests on modified Tetronic® macromer solutions would provide further insight into
the effect of terminal acrylate groups on gelation temperatures.

d. Ex Vivo Adhesive Testing on Rat Bladder
 Pressure testing of rat bladders was limited to a single loading cycle until failure.
Subjecting the rat bladder to repeated cycles of pressure loading will allow for
assessing long-term strength and durability of the adhesive.
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B.

Future Work

 Evaluating the swelling behavior of T304-acrylate
o Rationale: In order to ensure the adhesive does not lose its mechanical
strength or cause compression in surrounding tissues
 Testing the hydrogel-based adhesive on the bladder both ex vivo and in vivo
using larger animal models
o Rationale: Tests on larger animal models are a necessary step after small
animal models (rats) before ultimately moving onto clinical trials.
 Incorporation of a controlled biodegradable feature to the formulation
o Rationale: Tetronic® polymers go through hydrolytic degradation, so a
feature that enables controlled biodegradation will extend the amount of
time for which the adhesive will be effective.
 Development of a user-friendly application tool for surgical procedures
o Rationale: Ease of application is one of the characteristics of an ideal
surgical adhesive. The application mechanism must take into account the
two separate parts of the hydrogel-based adhesive: the Tetronic®
component and the thiol-containing crosslinker component.
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APPENDICES
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Appendix A: Additional Literature Review on Tissue Adhesives
a. Cyanoacrylate
1. Leggat et al. (2007)
The application of adhesive cyanoacrylate film strengthens by rapid polymerization,
usually within 5–60 seconds, catalyzed by hydroxyl groups on the surface being glued.
Earlier research work proposed that cyanoacrylate adhesives may generate lipid
hydroperoxides, which in turn activate prostaglandin and thromboxane biosynthesis.
These adhesives have also demonstrated the capacity to oxidize and lyse cell membranes,
somewhat explaining the reason behind the presence of particular thrombotic events
associated with necrosis when cyanoacrylates are used in vivo. In general, cyanoacrylate
has been shown to cause inflammation and tissue necrosis in vivo when used as a tissue
adhesive.20

2. Mizrahi et al. (2011)
Methodology in one study involved synthesizing the cyanoacrylates by condensation and
Knoevenagel reaction followed by characterization of the product by 1H NMR
spectroscopy. Mechanical testing was initially performed using an Instron universal
testing machine on aluminum specimens, with 5 microliters of the monomer applied to
each of the two specimens. The peak detachment force (N) and modulus were determined
after the probe was withdrawn at a rate of 0.1 mm/min. Similar experiments were
performed using strips of fresh skin harvested from 10 rats. 25 microliters of each glue
type was applied to cross-sectional cuts of 2 x 6 cm strips of skin with specimens
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stretched at a rate of 10 mm/min. Furthermore, the cytotoxicity of the different
cyanoacrylates was evaluated by exposing cells to the polymerized glues either by direct
contact (‘‘direct’’) or indirectly by exposing cells to the medium (DMEM) in contact
with the polymerized glues (‘‘indirect’’). And finally to test biocompatibility, Skin
incisions of 1.5 cm were made in anesthetized rats with 20 microliters of cyanoacrylate
applied to the resulting pouch. After 12 days, the rats were killed via carbon dioxide, and
the skin surrounding the glues was analyzed using histology.14

Results showed that yields of the synthesized monomers reduced with increasing sidechain length, possibly due to higher boiling points and larger degrees of side-chain
entanglement with increasing length. For mechanical testing, load values at rupture were
between 20 and 30 Newtons, consistent with previous studies for other cyanoacrylate
glues used ex vivo. Also, increasing side chain length was proven to increase the elasticity
of the polymer as well as decrease adhesive strength (although all strengths were still
classified as “useful”. With regard to cytotoxicity, monomers with longer side chains had
less toxicity both in vivo and in vitro. Biocompatibility findings demonstrated that
animals injected with cyanoacrylates comprised of longer side-chains had inflammation
without necrosis while those injected with monomers comprised of shorter side-chains
displayed serious tissue responses with prominent inflammation and necrosis.
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3. Mobley et al. (2002)
The binding strength of cyanoacrylates improved when the octyl-2 isomer was introduced
due to its approximately 4-fold three dimensional breaking strength increase in
comparison with its predecessor. Another advantage of this newest cyanoacrylate type is
that it possesses an antimicrobial activity that have been shown to have positive effects
on posttraumatic laceration.15

4. Reese et al. (2001)
Additionally, data acquired from numerous clinical trials have shown that rates of wound
dehiscence, hematoma formation and infection in cyanoacrylate-based adhesives are
nearly identical to those found in sutures repairs.13

b. BioGlue
1. Furst et al. (2005)
One study sought to evaluate the amount of glutaraldehyde released from BioGlue, the
effect of cytotoxicity on cultured cells (both in vivo and in vitro), and the local reaction of
rabbit lung, liver and aortic tissues to BioGlue. In the rabbit lung and liver models, a
fibrin sealant was used as the control group. With respect to experimental procedure,
BioGlue was prepared according to manufacturer instructions, allowed to polymerize for
2 minutes, and then overlaid with 5 ml of saline solution. The resulting supernatants were
then harvested and analyzed to determine content of glutaraldehyde. The cytotoxic effect
of BioGlue was evaluated by adding the supernatants to either human embryo fibroblasts
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(MRC5) or mouse myoblasts (C2C12). In vivo toxicity was measured on three different
tissues by applying BioGlue onto a rabbit partial lung resection, a liver abrasion, or an
intact abdominal aorta. Transverse tissue samples were stained with hematoxylin and
eosin and histologically assessed 2 and 7 days after application.23

2. LeMaire et al. (2002)
To test their hypothesis, LeMaire et al. first subjected ten 4-week-old domestic piglets
(8.0 ±1.4 kg) to general anesthesia. Next, under sterile conditions, the infrarenal
abdominal aorta was exposed through a midline laparotomy after which the aorta was
transected at the midpoint between the renal arteries and the bifurcation. A 2 mm ring of
aorta was removed from the proximal stump and cut longitudinally to allow for accurate
measurement of the aorta’s circumference. Finally, an end-to-end aorto-aortic
anastomosis was performed with interrupted 6-0 polypropylene sutures. Following
verification of patency using an aortogram, five piglets were assigned to either the
BioGlue group or control group. For the experimental group, a layer of BioGlue was
applied around the entire anastomosis as per manufacturer instructions. After a 7-week
growth period, the aortas were excised for morphometric analysis and histopathology.
Histologic sections of 5 microns were prepared using hematoxylin and eosin as well as
Geske’ stains, while for the morphometric analysis, aortic growth was evaluated by
calculating the changes in outer circumference and aortic area over the 7-week growth
period.
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Initial results from this study showed that weight gains were similar in both the
experimental and control groups. Yet, in pigs treated with BioGlue, aortic circumference
increased less, 1.5 ± 0.8 mm, versus 2.7 ±0.8 mm for the control group (p=0.054).
Moreover, BioGlue animals developed a 33.9% stenosis of the aortic lumen area against
3.7% in the controls (p =0.038). Histological results demonstrated normal postoperative
changes in the anastomotic sections of the control animals, including suture granulomas
and a mild increase in adventitial connective tissue. In comparisons, similar sections in
the BioGlue animals showed macrophage infiltration, dystrophic calcification, and
presence of foreign body giant cells. The group also found that the piglets treated with
BioGlue showed evidence of major fibrosis in the area surrounding the aorta.22

c. Fibrin Glue
1. Radosevich et al. (1997)
Fibrin glues are biological, biodegradable products that do not cause serious negative
reactions of tissue or induce necrosis/inflammation, which is in contrast to synthetic
sealants. Fibrin binds to biological tissues either by covalent, hydrogen or other
electrostatic bonds. Additionally, fibrin binds covalently to fibronectin and collagen by
way of factor XIIIa.24
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2. Cho et al. (2011)
There are certain drawbacks with naturally derived products such as fibrin glue and
BioGlue. These risks involve the possibility of viral transmission, hypersensitive
reactions to bovine proteins, and relatively low mechanical properties.12

3. Traver et al. (2006)
The composition of the commercial types of fibrin glue varies, but there are distinct
similarities such as incorporation of a 2-vial system containing fibrinogen, thrombin,
factor XIII, and calcium. The mechanism by which fibrin glue operates is actually a
mimic of the final steps of the natural coagulation cascade experienced by the human
body: thrombin activates factor XIII, which stabilizes the blood clot, by stimulating
crosslinking of the fibrin chains to long fibrin strands. Preparation takes 15 minutes and
application is performed using a double-barrel syringe system.17

4. Mobley et al. (2002)
This type of tissue adhesive has the longest history, and therefore, the broadest range of
applications. Recently, enhanced tensile strength by using pooled plasma has been shown
to increase fibrinogen production leading to more versatility for fibrin products in facial
reconstruction. Also, higher concentrations of thrombin in fibrin lead to quicker clot
formation and are ideal for hemostasis. Finally, an advantage of the double-barrel syringe
method of mixing is uniform mixing of the components, but disadvantages lie in
complexity and needle clogging As a result, a more sophisticated system of application,
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the Hemamyst aerosol spray device (Haemacure) is used. This is a gas pressurized system
using pressures of 5 to 10 liters/ min. The components are mixed in a pressurized gas
stream, allowing for more thorough mixing of the components compared to the older
syringe systems.15

5. Reese et al. (2001)
Fibrin glues have displayed the ability to be effective in cardiovascular surgery for
hemostasis, sealing air leaks in lung procedures, control burn bleeding, and in treating
lymphatic leaks in the neck. Additionally, they are the only type of tissue adhesives that
promote healing.13

6. Artzi et al. (2009)
Fibrin glue contains an antiproteinase that in turn hinders the growth of vascular
granulation tissue and healing of surgical anastomoses.28 It is also characterized as having
relatively non-specific and minimally adhesive tissue interaction while demonstrating a
mild tissue response.45

7. Shazly et al. (2008)
Finally, fibrin glues are generally more biocompatible than cyanoacrylates, but introduce
a moderate risk of infectious transmission due to their biological origins.46
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d. Tetronic®
1. Cho et al. (2011)
Acrylated macromers were covalently crosslinked using dithiothreitol (DTT) as a donor of
the thiol group. Solutions of T1107/T904 acrylate ratios and DTT at 4°C were mixed at a
1:1 thiol:acrylate molar ratio(30% weight/volume final Tetronic® concentration). Also,
viscosity of the poloaxmine solutions were was characterized at three different
temperatures using a rheometer (Physical MCR 300). The macromers were also subjected
to thermally-induced noncovalent gelation assessed by a tube inversion method. Tissue
bond strength was examined using rat skin; various hydrogel solutions mixed with DTT
were applied to a 1 cm x1 cm area of one skin strip and another skin strip was placed over
it. Bonding strength was calculated as the maximum load divided by the bonded area.
Tensile testing on all samples was performed after overnight equilibration at 4 and 37°C
where samples were cut into dog-bone shaped and subjected to uniaxial testing on an MTS
Synergie 100 machine at 20% strain and relaxation. Finally, cytotoxicity tests were
conducted using normal human dermal fibroblasts.12

In general, Tetronic®-based hydrogels are expected to bond to native tissue by way of
mechanical interactions with the tissue microarchitecture. Additionally, they can bond
through covalent crosslinking of free thiols present in ECM proteins. The amount of free
thiols present may vary based on exposure time to DTT during gelation (larger time
periods increase thiol number).12
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Appendix B: Complete Tetronic®/DTT Mixing Table

Table B.1: Full Tetronic®/DTT mixing table (bolded formulations used in
mechanical testing)
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Appendix C: Previous Mechanical Tests Using Tetronic®
Unpublished results from previous experiments conducted in our lab are presented below
(Figure C.1). The graphs display the maximum tension (N/cm) for n=9 tests per ratio and
shear adherence (Pa) for n=6 tests per ratio achieved for various blend ratios of T904acrylate/T1107-acrylate. Maximum tension results were obtained via end-to-end tests
while shear adherence testing followed a different protocol whereby a 4.9 mm-diameter
circular defect was created in a wide, ¾ inch-wide collagen sheet and placed over a
narrow, ½ inch-wide sheet with a stainless steel washer used to limit excessive spreading.
Next, 75 µl of the Tetronic®/DTT mix was applied to the center of the defect to form a
hydrogel rivet that maintained contact between the two sheets. Finally, a similar curing
time and mechanical testing procedure as the end-to-end test was observed.
Largest average maximum tension values achieved for end-to-end tests of T904acrylate/T1107-acrylate ratios were 0.43± 0.06 N/cm (mean ± SEM) at a ratio of 50/50
and 0.28± 0.04 N/cm for a ratio of 75/25, respectively at 50wt %. In comparison, the
highest average maximum shear adherence values were 18,123 ± 1650 Pa for the 75/25
ratio and 13,801 ± 1733 Pa at a ratio of 50/50, also both at 50wt %. However, the PEG
control was found to have the largest value for these tests with 23, 152 ± 8782 Pa.
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Figure C.1: End-to-End (left) and Shear Adherence
(right) configuration results for T904-acrylate/T1107acrylate ratios at 40wt %, 50wt %, and PEG control
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